QR Code

The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy.

The prognosis for people with the high-grade brain tumor glioblastoma is very poor, due largely to low cell death in response to genotoxic therapy. The transcription factor BCL6, a protein that normally suppresses the DNA damage response during immune cell maturation, and a known driver of B-cell ly...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Marie-Sophie Fabre, Nicole M Stanton, Tania L Slatter, Samuel Lee, Dinindu Senanayake, Rosemary M A Gordon, M Leticia Castro, Matthew R Rowe, Ahmad Taha, Janice A Royds, Noelyn Hung, Ari M Melnick, Melanie J McConnell
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Public Library of Science (PLoS) 2020-01-01
Rangatū:PLoS ONE
Urunga tuihono:https://doi.org/10.1371/journal.pone.0231470
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite